The virus–receptor interaction in the replication of feline immunodeficiency virus (FIV)
Brian J Willett and Margaret J Hosie

The feline and human immunodeficiency viruses (FIV and HIV) target helper T cells selectively, and in doing so they induce a profound immune dysfunction. The primary determinant of HIV cell tropism is the expression pattern of the primary viral receptor CD4 and co-receptor(s), such as CXCR4 and CCR5. FIV employs a distinct strategy to target helper T cells; a high affinity interaction with CD134 (OX40) is followed by binding of the virus to its sole co-receptor, CXCR4. Recent studies have demonstrated that the way in which FIV interacts with its primary receptor, CD134, alters as infection progresses, changing the cell tropism of the virus. This review examines the contribution of the virus–receptor interaction to replication in vivo as well as the significance of these findings to the development of vaccines and therapeutics.

Addresses
MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom

Corresponding author: Willett, Brian J (Brian.Willett@glasgow.ac.uk)

Current Opinion in Virology 2013, 3:670–675
This review comes from a themed issue on Virus replication in animals and plants
Edited by Ben Berkhourt and Kuan-Teh Jeang
For a complete overview see the Issue and the Editorial
Available online 28th August 2013
1879-6257 © 2013 The Authors. Published by Elsevier B.V.
Open access under CC BY license.
http://dx.doi.org/10.1016/j.coviro.2013.08.003

Introduction
The genus Felis is thought to have emerged close to 6.2 million years ago, during the late Miocene epoch [1]. Genetically, domestic cats are indistinguishable from the African wildcat, Felis sylvestris lybica, and archaeological evidence confirms that the close relationship between cats and humans was evident nearly 10 000 years ago in the Middle East [2]. The Felis lineage has suffered invasions by viruses from three subfamilies of the retroviridae, the spumavirinae FeFV (feline foamy virus), the gammaretrovirinae FeLV (feline leukaemia virus), and the lentivirinae FIV (feline immunodeficiency virus). Lentiviruses are endemic in Felidae species (reviewed in [3]) and appear to have invaded species such as the American puma (P. concolor) many thousands of years ago, prior to the spread of pumas from South America to North America (10–12 000 years ago, after the last ice age). In contrast, the absence of lentiviruses from the majority of species closely related to the domestic cat suggests a recent introduction and spread subsequent to domestication. The relatively recent spread of FIV through the domestic cat population and the striking similarities between the pathogenesis of FIV in cats, and of AIDS in HIV-infected individuals offers a unique opportunity to compare the evolution of the host–virus relationship and the development of immunity to infection.

FIV targets CD4+ helper T cells via an initial high affinity interaction between Env and CD134 (OX40) [4*,5*] and a subsequent interaction with the chemokine receptor CXCR4 [6,7]. Expression of CD134 in the cat is restricted largely to activated CD4+ T cells [8*]. Accordingly, FIV infection of the cat results in a progressive depletion of CD4+ helper T cells and the development of an AIDS-like immune dysfunction. The ensuing immunodeficiency manifests with chronic gingivitis and stomatitis, anorexia, cachexia, neurological signs and an increased incidence of malignancy.

Although the selective targeting of FIV to helper T cells may be explained by the restricted expression pattern of CD134, in early infection, the primary cellular targets for the virus are not only CD4+ helper T cells, but also monocytes. Later in infection the tropism of the virus extends further to encompass both CD8+ T cells and B cells (reviewed in [9]). CD134 was first described as a surface antigen that was expressed almost exclusively on CD4+ T cells [10], thus the extended tropism of FIV during the course of infection would seem counter-intuitive. The development of antibody reagents with which the surface expression of feline CD134 may be measured, confirmed the expression of CD134 on feline CD4+ T cells [5*,8*] and monocyte-derived macrophages [8*], with lower levels of expression on a minor population of activated CD8+ T cells and on CD45R+ (B220) B cells [8*] (Figure 1). The up-regulation of CD134 on feline CD4+ T cells following activation [4*,5*], and the high levels of surface expression achieved [8*], are consistent with the selective targeting of these cells in early infection. While CD134 expression is ostensibly undetectable on feline peripheral blood (CD14+) monocytes, weak expression can be detected on splenic macrophages.
in culture and is upregulated following activation with lipopolysaccharide [8*]. Although CD134 is expressed at lower levels on macrophages than on activated CD4+ helper T cells, since macrophages are rich in CXCR4, a scenario may be envisaged whereby following initial infection and spread, the virus disseminates into compartments where CD134 expression is a limiting factor, principally cells of the monocyte/macrophage lineage, and as yet uncharacterised subpopulations of B220+ B cells and activated CD8+ T cells.

**Not all FIVs bind CD134 in the same way**

The primary determinant of the FIV Env–CD134 interaction has been mapped to the first cysteine-rich domain (CRD1) of CD134 [11**,12**]. As human CD134 does not mediate FIV infection [4**] (one of the primary barriers to the transmission of FIV from cats to humans), chimeric CD134 molecules based on human CD134 and which bear the CRD1 of feline CD134 will support infection with selected strains of FIV [11**,12**]. Indeed, using this approach, a fully functional receptor for the PPR strain of FIV could be reconstituted by exchanging residues H45S, R59G, S60D, N62D, V64K in human CD134 [11**]. Importantly, well-characterised pathogenic strains of FIV, namely C-PGammer and GL8 (Glasgow-8) require additional determinants in the second cysteine-rich domain (CRD-2) of CD134 for infection [13**]. C-PGammer was derived by serial passage of plasma-borne virus during the acute phase of infection [14] while GL8 was isolated from a cat during a brief episode of illness during the protracted latent period of infection (subsequently the cat lived for a further eight years). Thus, these viruses are likely representative of viruses that dominate in early infection and, as such, may share properties with viruses that are transmitted between cats in nature. Accordingly, C-PGammer and GL8-like viruses may serve as biologically relevant challenge strains for trials of candidate vaccines. The amino acid motif 78NYE80 at the crown of a loop in CD134 CRD2 that participates in the interaction between CD134 and its cognate ligand (CD134L) is the essential determinant in CRD2 for CD134-usage by C-PGammer and GL8 (Figure 2). That GL8 and C-PGammer should be dependent upon residues distal to the projected Env binding face on CD134 is intriguing and may indicate that these viruses
recognise a specific CD134 conformation that is sensitive to the CD134L–CD134 interaction [15*].

While the residues on CD134 that are important for FIV Env binding have been described [11**,12*,13**], the corresponding receptor binding determinants on Env are less well characterised. It is known that, with disease progression, viral variants emerge which infect host cells via a direct interaction with CXCR4 (CD134-independent infection). Critical determinants of CD134-independence reside in the V3-loop and single glutamate to lysine mutations in residues 407 and 409 of V3 promote CXCR4-dependent syncytium formation [16]. In *vivo*, there is a strong selective pressure to restore a glutamate residue at these positions and revert to virulence [16]. One of the driving forces for this reversion may be escape from neutralising antibodies induced by CD134-binding; a CD134-independent E407K mutant of PPR was readily susceptible to CD134-dependent neutralising antibodies [17].

**Evolution of CD134 usage in vivo**

The virus–receptor interaction is a major determinant of the *in vivo* replicative capacity of HIV. For example, *ex vivo* analyses of primary HIV-1 isolates revealed that viral fitness mapped to the env gene [18,19]. Similarly, a comparison of the *env* from two primary isolates of HIV-1 demonstrated that the reduced fitness associated with a clade C Env was associated with weak cell surface binding, inefficient entry, and an increased sensitivity to CCR5 antagonists and fusion inhibitors [20]. Moreover, HIV-1 clade B envelopes from early infection tend to harbour amino acid signatures that favour efficient expression of Env in infected cells, enhancing Env incorporation into nascent virions and facilitating replication to a high titre [21,22]. These signature sequences are lost during chronic infection under selective pressure from the adaptive immune response [21,22]. In this context, the requirement for the 78NYE80 motif within the CRD2 of CD134 for both C-PGammer and GL8 EnvS may reflect a more efficient interaction between the viruses and their receptors. While infection with C-PGammer and GL8 is CRD2-dependent, strains such as PPR and B2542 have no such requirement. We postulated that CRD2-dependent infection might represent a feature of viruses that dominate ‘early’ in infection, facilitating both transmission and infection. Following establishment in the host, variants may then emerge that have a reduced requirement for an interaction with CRD2 of CD134, and in some cases may even lose the requirement for CRD2-binding altogether (as in PPR and B2542). This working hypothesis predicts that CRD2-independent viruses will be more prevalent in the ‘late’ stage of infection. In order to test this hypothesis, the receptor usage of viruses isolated six years post-infection with a clonal preparation of the CRD2-dependent GL8 strain was examined [23*]. While viral variants were identified that remained near identical to the challenge inoculum, additional variants were identified that displayed differences in the amino acid sequence of Env that switched the viral phenotype to CRD2-independent. Furthermore, these viruses displayed altered sensitivities to antagonists of the Env–CD134 interaction. While GL8 was markedly CRD2-dependent, resistant to anti-CD134 antibody and soluble CD134L (sCD134L) and sensitive to soluble CD134 (sCD134); variants that evolved *in vivo* were highly sensitive to anti-CD134 antibody, sensitive to sCD134L and resistant to sCD134 [23*]. That ‘late’ variants of GL8 should be sensitive to inhibition by anti-CD134 antibody is intriguing and may be significant, given that autoantibodies against CD134 have been detected in a proportion of FIV-infected cats [24*] and these autoantibodies were capable of blocking infection with the CRD2-independent PPR strain of FIV [24*]. Binding of the autoantibodies recognising CD134 in FIV infected cats required pre-engagement of CD134 with Env [24*], reminiscent of the polyreactive CD4-induced antibody 21c that recognises the HIV-1 Env–CD4 complex and binds determinants on both Env and CD4 [25]. Polyclonal B cell activation is a feature of both FIV and HIV infections and anti-CD4 autoantibodies have been well documented in HIV infection. Whether anti-CD134
and CD4 autoantibodies represent an anti-idiotypic response to antibodies raised against the viral Env protein or are epiphenomena related to the generalised immune dysregulation is unclear; nevertheless, the presence of such antibodies in the sera of FIV-infected cats may have the direct effect of suppressing the emergence of CRD2-independent viruses.

Engagement of CD4+ T cell-expressed CD134 by antigen presenting cell (APC)-expressed CD134L enhances the expansion and survival of antigen-specific CD4+ T cells (reviewed in [26]). Similarly, CD134L expressed on CD4+ T cells may contribute to the maintenance of CD4+ T cell longevity through T cell–T cell interactions [27]. Accordingly, the FIV–CD134 interaction may influence profoundly the development of antigen-specific immune responses as FIV will target preferentially the very cells that have been triggered to expand in response to infection, just as HIV infects HIV-specific CD4+ T cells preferentially [28]. Whether, APC-expressed CD134L, locally released soluble CD134 and CD134L, or anti-CD134 autoantibodies influence viral entry and expansion in vico remains to be established. However, as the CD134L–CD134 interaction is a prerequisite for the expansion of antigen-specific CD4+ T cells, it would seem likely that the virus would have evolved to associate with the ligand bound form of CD134. Support for this model comes from structural studies indicating that the primary binding face for Env on CD134 is distinct from the CD134L-binding face mapped by X-ray crystallography [29*]. Accessibility of the FIV Env binding site on the ligand-engaged form of CD134 may facilitate the transmission of FIV bound to the surface of dendritic cells (through DC-SIGN [30]) to adjacent CD134-expressing CD4+ T cells. However, as FIV infection is modulated by engagement of CD134 by CD134L [15*], a scenario may also be envisaged in which the Env-CD134 interaction modulates signalling through CD134. CD134-engagement by CD134L recruits TNFR-associated factors (TRAFs) to the cytoplasmic tail of the molecule and triggers an NF-κB1-dependent signalling pathway; if native Env acts as a CD134 agonist, viral attachment to CD134 may promote the expansion and survival of the very target cells required for FIV replication. Conversely, if Env acts as an antagonist, attachment to CD134 may contribute to the selective depletion of FIV-specific CD4+ T cells.

**CD134-usage and transmission**

If CD134 CRD2-dependent infection is a signature of FIV isolates from the ‘early’ stage of infection, such ‘early’ virus strains would appear to be the most appropriate targets for vaccine development. Assuming that both CRD2-dependent and CRD2-independent viruses are transmitted from an infected animal to a recipient during biting, what happens to CRD2-independent viruses following transmission? Are CRD2-independent viruses filtered from the inoculum during the process of transmission, analogous to the filtering of X4 variants of HIV-1 as articulated in the ‘gatekeeper’ hypothesis [31,32]? To resolve this question, a synthetic FIV quasispecies was prepared comprising matched doses of six clonal variants, identical in gag and pol but with unique envs derived from either CRD2-dependent or independent variants of FIV GL8. Following experimental transmission of this reconstituted quasispecies to naive animals, a selective expansion of CRD2-dependent viruses was observed [33*]. CRD2-independent viruses failed to thrive in vivo, achieving lower proviral loads. Further, the failure of the CRD2-independent viruses to thrive was independent of early neutralising antibody or cytotoxic T cell responses [33**]. These data suggest that CRD2-dependent viruses are able to replicate more efficiently in the host. Thus, clear parallels exist between the dominance of CCR5-dependent strains of HIV-1 and CD134 CRD2-dependent strains of FIV during early infection, culminating in the efficient targeting of a specific CD4+ helper T cell population.

**What drives the emergence of CD134 CRD2-independent viruses?**

The Fel-O-Vax FIV vaccine (Pfizer Inc.) combines inactivated virus and inactivated cells with a proprietary adjuvant. At the core of the vaccine is the FL4 strain of FIV, a derivative of the prototypic (and CRD2-independent) Petaluma isolate of FIV. The Env of FL4 is curious in that it lacks two potential sites for N-linked glycosylation that are highly conserved amongst the majority of field strains of virus. The T271I and N342Y mutations in FL4 lie in a loop region that is similar in location to the V1V2 loop of HIV. When identical mutations were incorporated into the Envs of either GL8 or C-FGAmmer, receptor usage was switched from CRD2-dependent to CRD2-independent [34*]. Given the role of N-linked glycosylation in shielding Env from the humoral immune response, the humoral response to infection may offer a driving force for the switch from CRD2-dependent to CRD2-independent infection. Consistent with this hypothesis, viral variants that emerged in vivo following infection with a clonal preparation of GL8, and which resisted neutralisation by homologous serum, displayed a shift in receptor usage from CRD2-dependent to CRD-2 independent [23*]. For one variant, exchange of the hypervariable V5 loop of Env alone was sufficient to render the virus both neutralising antibody resistant and CRD2-independent [23*]. As polyclonal sera elicited in infected cats can be remarkably mono-specific, targeting single determinants in the variable loops of the virus [35,36], in vivo escape from neutralisation may be sufficient to drive the emergence of CRD2-independent viruses. In doing so, the progeny viruses may gain the ability to spread into additional cellular compartments through a direct (CD134-independent) interaction with CXCR4 [17].
Conclusions
The replication of FIV in vivo may be influenced by both host and viral factors; in this review we have focussed on the Env–CD134 interaction. However, replication may also be influenced by additional viral determinants; transcriptional regulation by the long terminal repeats (LTRs) and the accessory gene orfA [37–41] and the ability of the virus to evade intrinsic immune factors such as APOBEC proteins [38,42]. Given that the virus–receptor interaction is the initial event in retroviral replication, understanding the intricacies of the Env–CD134 relationship will inform future strategies for the development of both FIV vaccines and therapeutics. Moreover, as the lentiviruses of cats and humans have evolved two distinct strategies to selectively target infection of CD4+ helper T cells, inter-species comparisons offer a unique opportunity to discern what makes immunodeficiency-causing lentiviruses tick.

Acknowledgements
This work was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and The Wellcome Trust to MJH and BJW.

References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest

1. Johnson WE, Eizrik E, Pecon-Slattery J, Murphy WJ, Antunes A, Teeling E, O’Brien SJ: The late Miocene radiation of modern Felidae: a genetic assessment. Science 2006, 311:73-77.

2. Driscoll CA, Clutton-Brock J, Kitchener AC, O’Brien SJ: The taming of the cat. Genetic and archaeological findings that wildcats became housecats earlier – and in a different place – than previously thought. Sci Am 2009, 300:68-75.

3. Pecon-Slattery J, Troyer JL, Johnson WE, O’Brien SJ: Evolution of feline immunodeficiency virus in Felidae: implications for human health and wildlife ecology. Vet Immunol Immunopathol 2008, 123:32-44.

4. Shimojima M, Miyazawa T, Ikeda Y, McMonagle EL, Haining H, •• Akashi H, Takeuchi Y, Hosie MJ, Willett BJ: Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 2004, 303:1192-1195.

This publication describes the molecular cloning of the primary receptor for FIV, CD134. CD134 is demonstrated to be essential for infection with primary isolates of FIV and to be dependent on the co-expression of OCX4.

5. de Parseval A, Chatterji U, Sun P, Elder JH: Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc Natl Acad Sci U S A 2004, 101:13044-13049.

This publication demonstrates that feline CD134 is upregulated selectively on CD4+ T cells and mediates FIV Env binding and viral infection. Although FIV Env also bound to CD8+ T cells, this binding was CD134-dependent and did not mediate infection.

6. Willett BJ, Hosie MJ, Neil JC, Turner JD, Hosie JA: Common mechanism of infection by lentiviruses. Nature 1997, 385: 587.

7. Willett BJ, Picard L, Hosie MJ, Turner JD, Adema K, Clapham PR: Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 1997, 71:6407-6415.

8. Willett BJ, McMonagle EL, Logan N, Spiller OB, Schneider P, • Hosie MJ: Probing the interaction between the feline immunodeficiency virus and CD134 using a novel monoclonal antibody 76D and CD134 (OX40L). J Virol 2007, 81:9665-9679.

This publication describes the development of a feline CD134-specific monoclonal antibody with which the virus-receptor interaction could be dissected. While CD134-expression was restricted primarily to activated CD4+ T cells, low level expression could also be detected on a sub-population of activated CD8+ T cells, B cells and monocytes, consistent with the reported cell tropism of FIV in chronically infected cats.

9. Willett BJ, Hosie MJ: The feline immunodeficiency viruses: viral cell tropism and the pathogenesis of feline AIDS. In Lentiviruses and Macronphages. Edited by Desport M, Caister Academic Press; 2010:231-250.

10. Mallett S, Fossam S, Barclay AN: Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor. EMBO J 1990, 9:1063-1068.

11. de Parseval A, Chatterji U, Morris G, Sun P, Olson AJ, Elder JH: •• Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus. Nat Struct Mol Biol 2004, 12:60-66.

This publication describes the mapping of the FIV Env (SU) binding site on feline CD134. By substituting amino acid residues in CRD1 of feline CD134 with the corresponding residues from human CD134, the SU-binding site on CD134 was mapped to an external loop on the opposite face of the molecule to the CD134L binding site.

12. Willett BJ, McMonagle EL, Bonci F, Pistello M, Hosie MJ: Mapping the domains of CD134 as a functional receptor for feline immunodeficiency virus. J Virol 2006, 80:7744-7747.

13. Willett BJ, McMonagle EL, Ridha S, Hosie MJ: Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus (FIV). J Virol 2006, 80:3386-3394.

This publication demonstrates that isolates of FIV differ in the way they interact with CD134. Isolates such as GL8, CPGammer and NCUS1 are dependent of determinants in both CRD1 and CRD2 of CD134 while PPR and B2542 are able to infect via an interaction with CRD1 alone. This observation suggests the CD134–CD134L interaction may influence viral infectivity while conversely, the Env–CD134 interaction may modulate CD134-dependent expansion of antigen-dependent T cells.

14. Diehl LJ, Mathiasion-Dubard CK, O’Neil LL, Obert LA, Hoover EA: Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. J Virol 1995, 69:6149-6157.

15. Willett BJ, McMonagle EL, Logan N, Schneider P, Hosie MJ: • Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Mol Immunol 2009.

This publication describes the development of a stable trimeric form of feline CD134L and its biological properties. CRD2-dependent strains of FIV were found to be more sensitive to inhibition by soluble trimeric CD134L than CRD2-dependent strains, indicating that CRD2-dependent strains may be capable of infecting cells in which CD134 exists in a ligand-bound state.

16. Hosie MJ, Willett BJ, Klein D, Dunsford TH, Cannon C, Shimojima M, Neil JC, Jarrett O: Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J Virol 2002, 76:6062-6072.

17. Hu QY, Fink E, Elder JH: Mapping of receptor binding interactions with the FIV surface glycoprotein (SU): implications regarding immune surveillance and cellular targets of infection. Retrovirology 2012, 2012:11-11.

18. Rangel HR, Weber J, Chaikarbory B, Gutierrez A, Marotta ML, Mirza M, Kaiser P, Martinez MA, Estes JA, Quinones-Mateu ME: Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol 2003, 77:9069-9073.

19. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quinones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M et al.: Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003, 77:1021-1038.

20. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, Arts EJ: Differences in the fitness of two diverse
wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005, 79:7121-7134.

21. Asmal M, Hellmann I, Liu WM, Keele BF, Perelson AS, Bhattacharya T, Gnanakaran S, Daniels M, Haynes BF, Korber BT et al.: A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS ONE 2011;6.

22. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Harber PT, Lapedes AS, Shen TY, Gaschen B, Krishnamoorthy M, Li H et al.: Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 2011;7.

23. Willett BJ, Kraase M, Logan N, Monagle EL, Samman A, Hosie MJ: Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody. Retrovirology 2010, 7:38.

This publication demonstrates that the humoral immune response to FIV may exert a selective pressure on the emergence of CRD2-independent viruses. Following in vivo infection with a clonal preparation of the CRD2-dependent GL8 strain of FIV, viral variants arise that resist neutralisation by homologous antibody and which are CRD2-independent. Resistance to neutralisation and CRD2-independence map to mutations in the fifth variable loop (V5) of Env.

24. Grant CK, Fink EA, Sundstrom M, Torbett BE, Elder JH: Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134. Proc Natl Acad Sci U S A 2009, 106:19980-19985.

This publication demonstrates the presence of anti-CD134 antibodies in sera from FIV-infected cats. The anti-CD134 antibodies appear to bind to a cryptic epitope on CD134 that is only revealed following SU-binding, while the presence of the anti-CD134 antibodies appears to correlate with lower viral loads.

25. Diikin R, Marcoveczio PM, Bjorkman PJ: Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol 2010, 17:608-613.

26. Croft M, So T, Duan W, Soroosh P: The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009, 229:173-191.

27. Soroosh P, Ine S, Sugamura K, Ishii N: OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol 2006, 176:5975-5987.

28. Duek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S et al.: HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.

29. Compaan DM, Hymowitz SG: The crystal structure of the costimulatory OX40-OX40L complex. Structure 2006, 14:1321-1330.

This publication describes the crystal structure of the CD134-CD134L (OX40-OX40L) complex. CD134 and CD134L interact as trimers, the FIV SU binding site localizes to the tip of CD134 CRD1 on the opposite face to the CD134L binding site.

30. de Parseval A, Su SV, Elder JH, Lee B: Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN. J Virol 2004, 78:2597-2600.

31. Margolis L, Shattock R: Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev Microbiol 2006, 4:312-317.

32. Grivel JC, Shattock RJ, Margolis LB: Selective transmission of RS HIV-1 variants: where is the gatekeeper? J Transl Med 2011, 9(Suppl 1):S6.

33. Willett BJ, Kraase M, Logan N, Monagle E, Varela M, Hosie MJ: Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies. PLoS ONE 2013, 8:e54871.

This publication demonstrates that CRD2-independent strains of FIV are at a replicative disadvantage following transmission. When a mixture of CRD2-dependent and independent strains of virus are transmitted experimentally, the CRD2-dependent strains expand preferentially in vivo. These observations suggest that in order to prevent transmission, vaccines should target CRD2-dependent strains of virus.

34. Willett BJ, Monagle EL, Logan N, Samman A, Hosie MJ: A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction. Retrovirology 2008, 5:77.

This publication demonstrates that the virus-receptor interaction is sensitive to the N-linked glycosylation of Env and that mutations in the V1/V2 loop homologue may shift the receptor interaction from CRD2-dependent to CRD2-independent. Such mutations are rare in field isolates, but are present in vaccine strains, indicating that deglycosylation of V1/V2 may have arisen during the cultivation of the vaccine strains in vitro. Deglycosylation of V1/V2 may expose novel determinants on Env that contribute to immunity to infection following vaccination.

35. Siebelink KH, Rimmelzwaan GF, Bosch ML, Melen RH, Osterhaus ADME: A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralisation. J Virol 1993, 67:2202-2208.

36. Samman A, Logan N, Monagle EL, Ishida T, Mochizuki M, Willett BJ, Hosie MJ: Neutralization of feline immunodeficiency virus by antibodies targeting the V5 loop of Env. J Gen Virol 2010, 91:242-249.

37. Thompson J, MacMillan M, Boegler K, Wood C, Elder JH, VandeWoude S: Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3 elements. PLoS ONE 2011, 6:e24020.

38. Troyer RM, Thompson J, Elder JH, Vandewoude S: Accessory genes confer high replication rate of virulent feline immunodeficiency virus (FIV). J Virol 2013.

39. Dean GA, Himathongkham S, Sperger EE: Differential cell tropism of feline immunodeficiency virus molecular clones in vivo. J Virol 1999, 73:2596-2603.

40. Pistello M, Moscardini M, Mazzetti P, Bonci F, Zaccaro L, Isola P, Freer G, Specter S, Matteucci D, Bendinelli M: Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 2002, 286:84-95.

41. Inoshima Y, Kohmoto M, Ikeda Y, Yamada K, Kawaguchi Y, Tomonaga K, Miyazawa T, Kai C, Umemura T, Mikami T: Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats. J Virol 1996, 70:8518-8526.

42. Munk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O’Brien SJ et al.: Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol 2008, 9:R48.

43. Baumann R, Yousefi S, Simon D, Russmann S, Mueller C, Simon HJ: Functional expression of CD134 by neutrophils. Eur J Immunol 2004, 34:2268-2275.

44. Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003, 31:3381-3385.